At the primary progression-free (PFS) analysis, the phase 3 EMBER-3 trial in endocrine pretreated patients with ER+, HER2- advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant vs. standard of care (SOC: fulvestrant or exemestane) in patients with ESR1 mutations (ESR1m) and with imlunestrant-abemaciclib vs. imlunestrant in all patients, regardless of ESR1m. Herein, we report updated efficacy from a…
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
Annals of Oncology | | K.L. Jhaveri, P. Neven, M.L. Casalnuovo, S-B. Kim, E. Tokunaga, P. Aftimos, C. Saura, J. O’Shaughnessy, N. Harbeck, L.A. Carey, G. Curigliano, J. Watanabe, E. Lim, J. Huang, Z. Qingyuan, A. Llombart-Cussac, C. Huang, B. Desai, Y. Limay, X.A. Wang, S. Cao, F.C. Bidard
Topics: breast-cancer, blood-cancer, clinical-trials